|
05 Jan 2021 |
Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States
|
|
05 Jan 2021 |
IconOVir Bio Raises $77 Million in Series A Financing to Develop Next-Generation Oncolytic Viruses to Treat Solid Tumors
|
|
30 Dec 2020 |
Altimmune Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B
|
|
30 Dec 2020 |
LyGenesis Receives FDA Clearance to Begin Phase 2a Trial of its Cell Therapy for Patients with End Stage Liver Disease, and also Closes $11 Million Convertible Debt Financing
|
|
30 Dec 2020 |
Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease
|
|
28 Dec 2020 |
Lysogene Reports Positive Biomarker Data With LYS-SAF302
|
|
25 Dec 2020 |
Audentes Therapeutics Announces FDA Lifts Hold on ASPIRO Clinical Trial of AT132 for Treatment of X-Linked Myotubular Myopathy (XLMTM)
|
|
24 Dec 2020 |
Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma
|
|
23 Dec 2020 |
A2 Biotherapeutics Enters Into Collaboration Agreement With Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
|
|
23 Dec 2020 |
Mustang Bio and City of Hope Announce Initiation of Phase 1 Clinical Trial of MB-101 (IL13Rα2-specific CAR T cells) to Treat Leptomeningeal Brain Tumors
|
|
23 Dec 2020 |
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
|
|
23 Dec 2020 |
Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
|
|
23 Dec 2020 |
BioEclipse Initiates Enrollment in Phase 1 Dose-Escalation Clinical Trial for CRX100
|
|
22 Dec 2020 |
Legend Biotech Announces Initiation of Rolling Submission of Biologics License Application to U.S. FDA Seeking Approval of BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed and/or Refractory Multiple Myeloma
|
|
22 Dec 2020 |
Taysha Gene Therapies Announces Queen’s University’s Receipt of Clinical Trial Application Approval from Health Canada for Phase 1/2 Clinical Trial of TSHA-101 for the Treatment of Infantile GM2 Gangliosidosis
|
|
22 Dec 2020 |
BioInvent and Transgene receive CTA approval for Phase l/lla trial of oncolytic virus BT-001 in solid tumors
|
|
18 Dec 2020 |
Glycostem and Ghent University sign license agreement on NK cell therapy technology
|
|
18 Dec 2020 |
Kiromic Announces Submission of Two IND Applications for PD1 Gamma-delta CAR - T cell Therapy with the FDA
|
|
18 Dec 2020 |
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses
|
|
16 Dec 2020 |
Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure
|
|
16 Dec 2020 |
Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases
|
|
16 Dec 2020 |
Glycostem announces treatment of first patient in pivotal phase I/IIa trial of oNKord® in patients with Acute Myeloid Leukemia
|
|
16 Dec 2020 |
INOVIO to Develop DNA-encoded Monoclonal Antibody (dMAb®) Candidates to Treat COVID-19 with Funding from the Defense Advanced Research Projects Agency (DARPA) and the Department of Defense's (DoD) Joint Program Executive Office for Chemical, Biological, R
|
|
16 Dec 2020 |
Kite’s Tecartus™ (KTE-X19) Granted Conditional Marketing Authorization for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma in Europe
|
|
14 Dec 2020 |
Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B
|
